Literature DB >> 27683063

Psychometric properties of the Revised Fibromyalgia Impact Questionnaire (FIQR) - a contribution to the Portuguese validation of the scale.

C Costa, A M Pinto, A T Pereira, M Marques, A Macedo, J A Pereira da Silva.   

Abstract

BACKGROUND: Fibromyalgia (FM) remains a relatively misunderstood and clinically challenging condition that impact significantly in the individual´s life, impairing global functioning and diminishing quality of life. Management is complex and frequently unsatisfactory, requiring personal tailoring and adaptation of interventions according to the fluctuations of the disease manifestations and their response to therapy. The use of comprehensive and quantified assessment tools constitutes, therefore, an essential component of the management of patients with FM. The Revised Fibromyalgia Impact Questionnaire (FIQR) is currently one of the most used and well validated instruments to assess functional (in)capacity and global impact of FM and associated symptoms.
OBJECTIVES: To translate to Portuguese the FIQR and to study its psychometric properties.
MATERIAL AND METHODS: The total sample comprised 103 women with fibromyalgia, defined according to the established criteria for FM. A self-report battery composed by the Revised Fibromyalgia Impact Questionnaire (FIQR), the Portuguese version of Beck Depression Inventory-II (BDI-II) and the Profile of Mood States (PoMS) was administered. The FIQR was re-administered to twenty-four participants, six weeks after the first evaluation. Internal reliability was assessed through Cronbach's alpha, corrected item-total score correlations and alpha if item deleted. Spearman and Pearson correlations along with repeated measures tests were computed to assess the temporal stability of the scale. Convergent and divergent validity were assessed via Spearman and Pearson correlations.
RESULTS: The FIQR demonstrated a good to very good internal consistency (from α = 0.87 to α = 0.94). All items correlated to a good degree (above 0.30) to the total score and contributed significantly to the overall reliability. Moreover, FIQR presented a good temporal stability (from r = .617 to r = .886, p ≤ .001) and favorable convergent and discriminant validity with depressive symptoms (r > .289, p ≤ .01) and positive (r > -.186, p > .05) and negative affect (r > .206, p ≤ .05).
CONCLUSIONS: The Portuguese version of the FIQR demonstrated good psychometric properties, which renders it a proper and valuable tool to be used in different settings.

Entities:  

Mesh:

Year:  2016        PMID: 27683063

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  4 in total

1.  Tobacco Use in Fibromyalgia Is Associated With Cognitive Dysfunction: A Prospective Questionnaire Study.

Authors:  Lin Ge; Ryan S D'Souza; Terry Oh; Ann Vincent; Arya B Mohabbat; Jason Eldrige; Li Jiang; Mary O Whipple; Samantha J McAllister; Zhen Wang; Wenchun Qu; William D Mauck
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-02-26

2.  A study protocol for a randomized controlled trial of an anti-inflammatory nutritional intervention in patients with fibromyalgia.

Authors:  Ana Rita Silva; Alexandra Bernardo; Maria Fernanda de Mesquita; José Vaz Patto; Pedro Moreira; Maria Leonor Silva; Patrícia Padrão
Journal:  Trials       Date:  2021-03-09       Impact factor: 2.279

3.  An anti-inflammatory and low fermentable oligo, di, and monosaccharides and polyols diet improved patient reported outcomes in fibromyalgia: A randomized controlled trial.

Authors:  Ana Rita Silva; Alexandra Bernardo; Maria Fernanda de Mesquita; José Vaz-Patto; Pedro Moreira; Maria Leonor Silva; Patrícia Padrão
Journal:  Front Nutr       Date:  2022-08-15

4.  Contextualizing goal preferences in fear-avoidance models. Looking at fatigue as a disabling symptom in fibromyalgia patients.

Authors:  Cecilia Peñacoba; Irene López-Gómez; Maria Angeles Pastor-Mira; Sofía López-Roig; Carmen Ecija
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.